A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Awarded By

Contributors

Start/End

  • July 15, 2015 - November 30, 2019